Efficacy of a Dual-Epitope Dendritic Cell Vaccine as Part of Combined Immunotherapy for HER2-Expressing Breast Tumors.

Saved in:
Bibliographic Details
Title: Efficacy of a Dual-Epitope Dendritic Cell Vaccine as Part of Combined Immunotherapy for HER2-Expressing Breast Tumors.
Authors: Vincent BG; Division of Hematology, Department of Medicine, University of North Carolina, Chapel Hill, NC.; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC.; Department of Microbiology and Immunology, UNC School of Medicine, Marsico Hall, Chapel Hill, NC.; Program in Computational Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC., File DM; Division of Oncology, Department of Medicine, University of North Carolina, Chapel Hill, NC., McKinnon KP; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC., Moore DT; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC., Frelinger JA; Department of Microbiology and Immunology, UNC School of Medicine, Marsico Hall, Chapel Hill, NC., Collins EJ; Department of Microbiology and Immunology, UNC School of Medicine, Marsico Hall, Chapel Hill, NC., Ibrahim JG; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC., Bixby L; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC., Reisdorf S; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC., Laurie SJ; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC., Park YA; Department of Pathology and Laboratory Medicine, University of North Carolina, Chapel Hill, NC., Anders CK; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC.; Division of Oncology, Department of Medicine, University of North Carolina, Chapel Hill, NC., Collichio FA; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC.; Division of Oncology, Department of Medicine, University of North Carolina, Chapel Hill, NC., Muss HB; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC.; Division of Oncology, Department of Medicine, University of North Carolina, Chapel Hill, NC., Carey LA; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC.; Division of Oncology, Department of Medicine, University of North Carolina, Chapel Hill, NC., van Deventer HW; Division of Hematology, Department of Medicine, University of North Carolina, Chapel Hill, NC.; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC., Dees EC; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC.; Division of Oncology, Department of Medicine, University of North Carolina, Chapel Hill, NC., Serody JS; Division of Hematology, Department of Medicine, University of North Carolina, Chapel Hill, NC.; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC.; Department of Microbiology and Immunology, UNC School of Medicine, Marsico Hall, Chapel Hill, NC.; Program in Computational Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC.
Source: Journal of immunology (Baltimore, Md. : 1950) [J Immunol] 2023 Jul 15; Vol. 211 (2), pp. 219-228.
Publication Type: Clinical Trial, Phase II; Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Oxford University Press Country of Publication: England NLM ID: 2985117R Publication Model: Print Cited Medium: Internet ISSN: 1550-6606 (Electronic) Linking ISSN: 00221767 NLM ISO Abbreviation: J Immunol Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1550-6606
DOI:10.4049/jimmunol.2300077